Company History
2011
 ► TaiwanJ was incorporated.

2013
 ► TFDA approved to proceed JKB-122 HCV Phase II trial.
 ► TaiwanJ was officially named TaiwanJ Pharmaceuticals Co., Ltd.
 ► Closed the first capital increase, and engaged in lead compound JKB-122 clinical developments
 ► ITRI biomedical department team joined TaiwanJ.

2014
 ► Ministry of Economic Affairs approved "high-quality case accelerate plan" primary selection.
 ► TaiwanJ was selected "2014 Taiwan biomedical and agricultural industry talent contest" superior enterprise.

2015
 ► TaiwanJ relocated to Hsinchu Biomedical Science Park.
 ► FDA approved to proceed JKB-121 NASH Phase II trial in US TFDA approved to proceed JKB-122 NAFLD Phase II trial.
 ► TaiwanJ passed public company qualification, stock code 6549.
 ► TFDA approved to proceed JKB-122 AIH Phase II trial.
 ► TaiwanJ was approved by the Ministry of Economy as a "new drugs biotech company".
 ► TaiwanJ was invited to participate BioInvestment Forum 2015.
 ► FDA granted orphan drug designation for using JKB-122 to treat AIH.
 ► TaiwanJ registered as an emerging company in Taipei Exchange.

2016
 ► TaiwanJ was awarded the 13th National Innovation Award for "First-In-Class Drug for Chronic Liver Disease" in the Pharmaceutical and New Medical Technology Category by the Institute for Biotechnology and Medicine Industry.
 ► TaiwanJ collaborated with Academia Sinica and NTU and signed exclusive licensing agreement for dual target-drug development in cancer therapy.

2017
 ► Published an autoimmune hepatitis (AIH) article for JKB-122 in European Journal of Pharmacology.
 ► Obtained Excellent Piece Award in the Elite Group of the 6th Women Entrepreneurship Competition by Small & Medium Enterprise Administration, Ministry of Economic Affairs of Taiwan.

2018
 ► Reached the primary endpoint and partial secondary endpoints with significant effects for JKB-122 in the Phase 2 clinical trial on Non-Alcoholic Fatty Liver Disease (NAFLD).

2019
 ► Reached the primary endpoint and partial secondary endpoints with significant effects for JKB-122 in the Phase 2 clinical trial on Autoimmune Hepatitis (AIH).
 ► Signed the deal with Newsoara Biopharma for out-licensing the Asian rights of JKB-122 and co-development of JKB-133 for upfront and milestone payments of US$26M in addition to the royalty payment after marketing the drug.